ROS1 Biomarkers
News and reporting on ROS1 biomarkers.
AnHeart Therapeutics Begins Phase II Basket Trial of Taletrectinib in NTRK-Positive Solid Tumors
AnHeart licensed taletrectinib this month to Innovent Biologics, which will codevelop and commercialize the drug in greater China.
Zai Lab Begins Phase II Study of Repotrectinib in NSCLC, Solid Tumors in China
Zai Lab is conducting the trial in Greater China for Turning Point Therapeutics, which licensed repotrectinib to Zai last year.
LUNGevity Aims for Widespread Comprehensive Biomarker Test Access With New Patient-Facing Campaign
Premium
LUNGevity hopes to streamline patient education messaging and reach lung cancer patients in underserved communities who miss out on comprehensive testing.
Nuvalent Raises $135M in Series B Funding
The company will use the funding to advance its lead NSCLC treatments, a ROS inhibitor and ALK inhibitor, into the clinic.
Turning Point Therapeutics to Discuss Repotrectinib NSCLC Data With FDA
Interim data from the Phase II portion of the study in ROS1-positive non-small cell lung cancer showed an objective response rate of 93 percent.
Jun 4, 2019
May 16, 2019